Literature DB >> 17493429

Treatment options for hepatobiliary and pancreatic cancer.

Steven R Alberts1, Gregory J Gores, George P Kim, Lewis R Roberts, Michael L Kendrick, Charles B Rosen, Suresh T Chari, James A Martenson.   

Abstract

Hepatobiliary and pancreatic cancers account for 4% of all cancers in the United States. Traditionally, these cancers have had a high mortality rate and have been poorly responsive to therapy. Because of a growing number of treatment options, patients are now living longer. For hepatocellular carcinoma, a broad number of treatment options are available, including surgery, ablation, embolization, systemic therapy, and liver transplantation. Treatment options for cholangiocarcinoma include surgery, systemic therapy, and liver transplantation. For pancreatic cancer, surgery, radiation, and systemic therapy all have potential roles. This review provides an updated summary of diagnosis and assessment together with treatment options for this group of cancers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17493429     DOI: 10.4065/82.5.628

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  25 in total

1.  The novel monoclonal antibody HPC2 and N-cadherin distinguish pancreatic ductal adenocarcinoma from cholangiocarcinoma.

Authors:  Jody E Hooper; Terry K Morgan; Markus Grompe; Brett C Sheppard; Megan L Troxell; Christopher L Corless; Philip R Streeter
Journal:  Hum Pathol       Date:  2012-03-09       Impact factor: 3.466

Review 2.  Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment.

Authors:  Boris Blechacz; Gregory J Gores
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

3.  Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma.

Authors:  Deyali Chatterjee; Matthew H Katz; Asif Rashid; Jeannelyn S Estrella; Hua Wang; Gauri R Varadhachary; Robert A Wolff; Jeffrey E Lee; Peter W Pisters; James L Abbruzzese; Jason B Fleming; Huamin Wang
Journal:  Histopathology       Date:  2013-09-20       Impact factor: 5.087

4.  Armed and targeted measles virus for chemovirotherapy of pancreatic cancer.

Authors:  S Bossow; C Grossardt; A Temme; M F Leber; S Sawall; E P Rieber; R Cattaneo; C von Kalle; G Ungerechts
Journal:  Cancer Gene Ther       Date:  2011-06-24       Impact factor: 5.987

5.  High expression of long non-coding RNA NNT-AS1 facilitates progression of cholangiocarcinoma through promoting epithelial-mesenchymal transition.

Authors:  Yulei Gu; Chao Li; Lili Xiao; Juan Li; Hui Pei; Dong Xu; Yumin Jiang; Xiaofan Zhang; Luanluan Zhang; Kongfei Li; Zhiqiang Zhu; Xiaolong Chen
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

6.  Sodium iodide symporter (NIS)-mediated radiovirotherapy for pancreatic cancer.

Authors:  Alan R Penheiter; Troy R Wegman; Kelly L Classic; David Dingli; Claire E Bender; Stephen J Russell; Stephanie K Carlson
Journal:  AJR Am J Roentgenol       Date:  2010-08       Impact factor: 3.959

7.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.

Authors:  Shaji K Kumar; Joseph R Mikhael; Francis K Buadi; David Dingli; Angela Dispenzieri; Rafael Fonseca; Morie A Gertz; Philip R Greipp; Suzanne R Hayman; Robert A Kyle; Martha Q Lacy; John A Lust; Craig B Reeder; Vivek Roy; Stephen J Russell; Kristen E Detweiler Short; A Keith Stewart; Thomas E Witzig; Steven R Zeldenrust; Robert J Dalton; S Vincent Rajkumar; P Leif Bergsagel
Journal:  Mayo Clin Proc       Date:  2009-12       Impact factor: 7.616

Review 8.  Liver transplantation after radioembolization in a patient with unresectable HCC.

Authors:  Laura E Moreno Luna; Paul Y Kwo; Lewis R Roberts; Teresa A Mettler; Denise N Gansen; James C Andrews; Gregory A Wiseman; Vijay Laxmi Misra
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-11       Impact factor: 46.802

9.  Quantitative molecular imaging of viral therapy for pancreatic cancer using an engineered measles virus expressing the sodium-iodide symporter reporter gene.

Authors:  Stephanie K Carlson; Kelly L Classic; Elizabeth M Hadac; David Dingli; Claire E Bender; Bradley J Kemp; Stephen J Russell
Journal:  AJR Am J Roentgenol       Date:  2009-01       Impact factor: 3.959

Review 10.  Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma.

Authors:  Alphonse-E Sirica
Journal:  World J Gastroenterol       Date:  2008-12-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.